Published on Web 01/31/2002
Stereocontrolled Synthesis of (-)-Macrolactin A
Joseph P. Marino,*,† Michael S. McClure,*,† David P. Holub,†
Joa˜o V. Comasseto,‡ and Fab´ıo C. Tucci‡
Contribution from the Department of Chemistry, UniVersity of Michigan, Ann Arbor, Michigan
48109, and Instituto de Qu´ımica, UniVersidade de Sa˜o Paulo, Sa˜o Paulo 26077, Brazil
Received September 27, 2001. Revised Manuscript Received November 30, 2001
Abstract: The total synthesis of (-)-macrolactin A, a 24-membered macrolide, has been achieved using
a newly developed 1,3-diol synthon for the introduction of two key stereogenic centers. The synthon was
derived from sequential use of the Noyori asymmetric reduction followed by chiral sulfoxide methodology.
Tellurium-derived cuprate organometallics offered an efficient and highly stereoselective means for
installation of the C8 Z/E-diene, while the C15 E/E-segment was derived from a Julia-Lythgoe olefination.
Yamaguchi lactonization was used to secure the macrocycle in a convergent approach with the longest
linear sequence of 19 steps from Noyori alcohol 6.
Introduction
The macrolactins are a structurally diverse class of secondary
metabolites isolated from a deep-sea bacterium.1 The parent
aglycone, macrolactin A (Figure 1), is representative. Some
members of this class possess pendant glucose-â-pyrannosides,
while others differ in the oxidation state and degree of
unsaturation. Macrolactin A exhibits a broad spectrum of activity
with significant antiviral and cancer cell cytotoxic properties
including inhibition of B16-F10 murine melanoma cell replica-
tion with in vitro IC50 values of 3.5 µg/mL. Macrolactin A also
has implications for controlling human HIV replication and is
a potent inhibitor of Herpes simplex types I and II. Because of
its unique structural architecture and the potential for broad
therapeutic applications, macrolactin A has been an attractive
target for synthesis and has further led to the development of
novel synthetic methodology.2 Fenical and co-workers discov-
ered the macrolactins1 and reported with their initial findings
general structural assignments for macrolactins A-F. The
absolute stereochemistry was later established for macrolactins
B and F through degradation, chemical correlation, and 13C-
acetonide analysis.3 The stereochemical assignments for mac-
rolactin A were made initially through comparative spectral data,
but later were confirmed by Smith and Ott in the first total
Figure 1. (-)-Macrolactin A.
synthesis4 and later by Carreira and co-workers.5 Synthetic
efforts are essential for additional pharmacological investigations
and understanding the mode of action of these molecules.
Typical recoveries from 16 L of cell culture give 6-9 mg of
macrolactin A and less of the other macrolactins. Notably, the
bacterial source of the macrolactins apparently no longer
produces macrolactins A-E, only F.2a
Results and Discussion
We report herein the stereocontrolled synthesis of (-)-
macrolactin A based upon four principal components 2-5
(Scheme 1). This synthesis features the transmetalation of a
stereodefined Z-vinylic telluride, the novel application of chiral
sulfoxides, and the critical use of a recently developed, versatile
1,3-diol synthon. Our key disconnection involved assembly of
advanced intermediates 2 and 3 via a Julia-Lythgoe6 coupling.
The northern portion of the molecule containing the C7
stereocenter we envisioned would involve the asymmetric
addition of an organometallic, formally represented as subunit
5. Macrocyclic ring closure would consummate the synthesis
* To whom correspondence should be addressed. M.S.M., current
address: GlaxoSmithKline, Chemical Development, Research Triangle Park,
NC 27709.
† University of Michigan.
‡ Universidade de Sa˜o Paulo.
(1) Gustafson, K.; Roman, M.; Fenical, W. J. Am. Chem. Soc. 1989, 111, 7519.
(2) (a) Smith, A. B., III; Ott, G. R. J. Am. Chem. Soc. 1996, 118, 13095. (b)
Boyce, R. J.; Pattenden, G. Tetrahedron Lett. 1996, 37, 3501. (c) Donaldson,
W. A.; Bell, P. T.; Wang, Z.; Bennett, D. W. Tetrahedron Lett. 1994, 35,
5829. (d) Prahlad, V.; Donaldson, W. A. Tetrahedron Lett. 1996, 37, 9169.
(e) Tanimori, S.; Morita, Y.; Tsubota, M.; Nakayama, M. Synth. Commun.
1996, 26, 559. (f) Benvegnu, T.; Schio, L.; Le Floc’h, Y.; Gre´e, R. Synlett
1994, 505. (g) Benvegnu, T. J.; Gre´e, R. L. Tetrahedron 1996, 52, 11821.
(3) Rychnovsky, S. D.; Skalitzky, D. J.; Pathirana, C.; Jensen, P. R.; Fenical,
W. J. Am. Chem. Soc. 1992, 114, 671.
(4) Reference 2a and Smith, A. B., III; Ott, G. R. J. Am. Chem. Soc. 1998,
120, 3935.
(5) Kim, Y.; Singer, R. A.; Carreira, E. M. Angew. Chem., Int. Ed. 1998, 37,
1261.
(6) Julia, M.; Paris, J.-M. Tetrahedron Lett. 1973, 4833.
9
1664 VOL. 124, NO. 8, 2002 J. AM. CHEM. SOC.
10.1021/ja017177t CCC: $22.00 © 2002 American Chemical Society